LC
ABBV icon

Legacy CG’s AbbVie ABBV Stock Holding History

Legacy CG’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.07M Buy
28,096
+193
+0.7% +$41.5K 1.81% 24
2026
Q1 		$6.07M Buy
27,903
+256
+0.9% +$56.8K 1.69% 24
2025
Q4 		$6.32M Sell
27,647
-191
-0.7% -$43.5K 1.77% 22
2025
Q3 		$6.45M Buy
27,838
+14,257
+105% +$2.9M 1.82% 25
2025
Q2 		$2.52M Buy
+13,581
New +$2.52M 0.75% 43

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Legacy CG's ABBV Position: Q2 2026 in Review

Legacy CG increased its AbbVie (ABBV) stake by 0.69% in Q2 2026, buying an estimated $41.5K and bringing the position to 28,096 shares worth $7.07M. The position accounts for 1.81% of the portfolio, ranked #24.

Legacy CG first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Legacy CG held 28,096 shares of AbbVie worth $7.07M as of Q2 2026.
  • Legacy CG bought 193 AbbVie shares in Q2 2026, an estimated $41.5K.
  • AbbVie made up 1.81% of Legacy CG's portfolio in Q2 2026, its #24 holding.
  • Legacy CG first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
  • 4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Legacy CG's 13F filing for Q2 2026, filed 22 Jul 2026.